FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

30 letters match. Newest first.

  1. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  2. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  3. Swift Digital Group LLC dba Swadesii

    FDA warned Swadesii that its website sells unapproved drugs with claims to treat serious conditions including measles, cancer and Alzheimer's.

    High risk
  4. Green Vitality dba Gr33n

    FDA warned Green Vitality dba Gr33n that its Jimerito Honey Eye Drops are an unapproved new drug sold with disease-treatment claims.

    High risk
  5. My Holistic Honey c/o Shenzhen Qanhai Wanb Express Supply Chain Co., LTD

    FDA warned My Holistic Honey that its honey eye drops are an unapproved new drug sold with drug claims.

    High risk
  6. Homeopathic Educational Services dba Homeopathic Family Medicine

    FDA says Homeopathic Family Medicine sells unapproved Cineraria Maritima Eye Drops for cataracts online.

    High risk
  7. Mel Honey US

    FDA warned Mel Honey US that its Jimerito (Melipona) Honey eye drops are an unapproved new drug.

    High risk
  8. Supply Center USA

    Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.

    High risk
  9. Trew Balance

    FDA warned Trew Balance that its Trew Vision CBD Eye Drops are an unapproved new drug sold with disease-treatment claims.

    High risk
  10. Life Enthusiast Co-op

    FDA tells Life Enthusiast Co-op its three eye products sold online are unapproved new drugs.

    High risk
  11. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  12. Scope Health Inc

    FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.

    High risk
  13. Thea Pharma, Inc.

    FDA warns Thea Pharma that IVIZIA OTC lubricant eye drops are an unapproved and misbranded new drug.

    High risk
  14. EyeTech One, LLC

    FDA warns EyeTech One that its EYELIVIO lubricant eye ointment is an unapproved new drug and misbranded.

    Medium
  15. AACE Pharmaceuticals, Inc.

    AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.

    High risk
  16. OSRX, Inc.

    OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.

    High risk
  17. Aspen Pharmacare Holdings Limited

    FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.

    High risk
  18. Velocity Pharma LLC

    Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.

    High risk
  19. Optikem International Inc.

    FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.

    High risk
  20. EzriCare LLC

    EzriCare distributed non-sterile Artificial Tears made by a CMO with CGMP violations, linked to a Pseudomonas outbreak.

    High risk
  21. Southern Tier Home Infusion, Inc. dba Pharmacy Innovations

    FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.

    High risk
  22. DR Vitamins, LLC dba DR Vitamin Solutions

    FDA warned DR Vitamin Solutions that its eye drops are unapproved new drugs and misbranded.

    High risk
  23. CVS Health

    FDA told CVS Health its unapproved Pink Eye Relief Drops are an illegal new drug made by a manufacturer with serious quality violations.

    High risk
  24. TRP Company, Inc

    FDA warns TRP Company that its homeopathic eye drops and ointments are unapproved new drugs and may be adulterated.

    High risk
  25. Similasan AG

    Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.

    High risk
  26. K.C. Pharmaceuticals Inc.

    FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.

    High risk
  27. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  28. Pharmedica USA, LLC

    FDA found Pharmedica made ophthalmic and nasal drugs under insanitary conditions without required sterile controls.

    High risk
  29. Sterling Pharmaceutical Services, LLC

    Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.

    High risk
  30. Imprimis Rx LLC

    FDA warns Imprimis Rx over false, misleading promotion of compounded eye drug Pred-Moxi-Brom.

    Low